miRNA Profiling in Fixed Cancer Samples

Information

  • Research Project
  • 8264290
  • ApplicationId
    8264290
  • Core Project Number
    R44CA118785
  • Full Project Number
    6R44CA118785-04
  • Serial Number
    118785
  • FOA Number
    RFA-CA-06-006
  • Sub Project Id
  • Project Start Date
    6/1/2006 - 18 years ago
  • Project End Date
    5/31/2011 - 13 years ago
  • Program Officer Name
    RAHBAR, AMIR M
  • Budget Start Date
    5/25/2011 - 13 years ago
  • Budget End Date
    5/31/2011 - 13 years ago
  • Fiscal Year
    2009
  • Support Year
    4
  • Suffix
  • Award Notice Date
    9/16/2011 - 12 years ago
Organizations

miRNA Profiling in Fixed Cancer Samples

DESCRIPTION (provided by applicant): During Phase I of our proposed research, we will develop and validate procedures for recovering, labeling, and analyzing miRNAs from fixed tissue samples. The procedures will be based on the miRNA microarray and fixed tissue RNA isolation systems that we developed in other SBIR-funded programs. The development of our miRNA isolation and labeling procedures will be accomplished using a model system wherein mouse organs will be split and half is flash-frozen and the other half formalin-fixed using a procedure that is commonly employed in hospitals. The frozen and fixed samples will be processed to recover the miRNAs. The miRNAs from the fixed and frozen tissues will be independently labeled and analyzed using miRNA microarrays. The isolation, labeling, and hybridization procedures will be varied until the fixed samples yield the same miRNA expression profiles as the equivalent frozen samples. The fixed sample procedures will) then be used to analyze formalin fixed, human tissue samples to analyze miRNA profiles from multiple organs. The fixed tissue miRNA profiles will be compared to the profiles generated from frozen samples to verify that the fixed tissue miRNA profiling process can be used for stored, human fixed tissue samples. During Phase II of our research project, we will use the miRNA isolation, labeling and microarray analysis procedures developed during Phase I to analyze archived, fixed human cancer tissues to identify miRNAs with expression profiles that are significantly different from equivalent, normal tissues. The most interesting miRNAs or miRNA signatures might provide opportunities for diagnostic/prognostic assay development or even an intervention point for therapeutic agents.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    6
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    194716
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:194716\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ASURAGEN, INC.
  • Organization Department
  • Organization DUNS
    622988330
  • Organization City
    AUSTIN
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    78744
  • Organization District
    UNITED STATES